PMVP PMV Pharmaceuticals, Inc. - Common Stock
$1.24
价格 · 八月 19, 2026
截至...的财报数据 八月 14, 2026
52周区间
$1–$2
26% of range
分析师评级
BUY
12 analysts
目标价
$4
+223% upside
P/E (TTM)
-0.8
ROE
-63.4%
净利润率
-1226.8%
PMVP 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$1.24
市值
$66M
P/E (TTM)
-0.8
每股收益 (TTM)
$-1.48
营收 (TTM)
—
股息收益率
—
ROE
-63.4%
负债/权益
—
52周区间
$1 – $2
PMVP 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
Configure
10年表现 收入、净利润、利润率和每股收益趋势
营收与净利润
—
EPS
$-1.48
2020-12-31
→
2025-12-31
自由现金流
$-74M
2020-12-31
→
2025-12-31
利润率
-1226.8%
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
指标
5年趋势
PMVP
同行中位数
P/E (TTM)
-0.8
—
P/S (TTM) (市销率 (TTM))
10.4
165.8
P/B (市净率)
0.6
1.6
Price / FCF (股价/自由现金流)
-0.9
—
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
指标
5年趋势
PMVP
同行中位数
Operating Margin (营业利润率)
-1360.4%
—
Net Profit Margin (净利润率)
-1226.8%
-2229.6%
ROA
-50.5%
-64.3%
ROE
-63.4%
-102.1%
ROIC
-80.1%
—
财务健康 债务、流动性、偿付能力 — 资产负债表强度
指标
5年趋势
PMVP
同行中位数
Current Ratio (流动比率)
10.1
4.8
Quick Ratio (速动比率)
9.9
—
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
指标
5年趋势
PMVP
同行中位数
Revenue YoY (营收同比增长)
-40.5%
—
Revenue CAGR 3Y (营收3年复合年增长率)
20.4%
—
Revenue CAGR 5Y (营收5年复合年增长率)
57.6%
—
资本效率 资产周转率、库存周转率、应收账款周转率
指标
5年趋势
PMVP
同行中位数
PMVP 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
买入
12 位分析师
- 强烈买入 4 33.3%
- 买入 7 58.3%
- 持有 1 8.3%
- 卖出 0 0.0%
- 强烈卖出 0 0.0%
12个月价格目标
4 位分析师 · 2026-08-18
中位数
$4.00
← 低于所有目标
$1.24
最低
$3.00
最高
$5.00
中位数目标
$4.00
+222.6%
平均目标
$4.00
+222.6%
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
0.04%
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年3月31日 | $-0.34 | $-0.42 | 0.08% |
| 2025年12月31日 | $-0.34 | $-0.41 | 0.07% |
| 2025年9月30日 | $-0.40 | $-0.41 | 0.01% |
| 2025年6月30日 | $-0.41 | $-0.39 | -0.02% |
| 2025年3月31日 | $-0.34 | $-0.38 | 0.04% |
同行比较（GICS 子行业） 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| PMVP | $67M | -0.8 | -40.5% | -1226.8% | -63.4% | — |
| GOSS | $724M | -4.1 | -57.7% | -351.5% | 201.8% | — |
| CTOR | $170M | -6.0 | — | — | -61.5% | — |
| XBIT | — | -1.6 | — | — | — | — |
| TENX | $114M | -9.1 | — | — | -52.5% | — |
| MNOV | $64M | -5.5 | — | -2928.8% | -27.1% | — |
| BOLD | $27M | -0.5 | — | — | -46.7% | — |
| HRTX | $245M | -10.8 | 7.4% | -13.0% | 312.5% | 73.3% |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | — |
| EXOZ | $92M | -10.0 | — | — | -172.3% | — |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 13
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| R&D Expense | $70M | $59M | $56M | $52M | $36M | $24M | $21M | |
| SG&A Expense | $16M | $27M | $24M | $25M | $22M | $11M | $6M | |
| Operating Expenses | $86M | $85M | $80M | $77M | $58M | $35M | $27M | |
| Operating Income | $-86M | $-85M | $-80M | $-77M | $-58M | $-35M | $-27M | |
| Other Non-op | $6M | $11M | $11M | $4M | $470.0K | $508.0K | $1M | |
| Pretax Income | $-80M | $-75M | $-69M | $-73M | $-58M | $-34M | $-25M | |
| Income Tax | $-2M | $-16M | $2.0K | $-9.0K | $23.0K | $6.0K | $8.0K | |
| Net Income | $-78M | $-59M | $-69M | $-73M | $-58M | $-34M | $-25M | |
| EPS (Basic) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 | $-2.40 | · | |
| EPS (Diluted) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 | $-2.40 | · | |
| Shares (Basic) | 52,541,613 | 51,578,807 | 48,014,645 | 45,594,824 | 45,137,656 | 14,364,475 | · | |
| Shares (Diluted) | 52,541,613 | 51,578,807 | 48,014,645 | 45,594,824 | 45,137,656 | 14,364,475 | · | |
| EBITDA | $-86M | $-85M | $-80M | $-77M | $-58M | $-35M | · |
资产负债表 20
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $38M | $41M | $38M | $108M | $172M | $361M | $73M | |
| Short-term Investments | $75M | $129M | $165M | $133M | $125M | · | · | |
| Prepaid Expense | $2M | $6M | $4M | $5M | $3M | $3M | $607.0K | |
| Current Assets | $115M | $176M | $207M | $247M | $301M | $365M | $102M | |
| PP&E (Net) | $237.0K | $409.0K | $11M | $11M | $3M | $569.0K | $739.0K | |
| PP&E (Gross) | $2M | $2M | $14M | $13M | $5M | $2M | $2M | |
| Accum. Depreciation | $1M | $1M | $3M | $2M | $2M | $2M | $1M | |
| Other Non-current Assets | $297.0K | $235.0K | $190.0K | $313.0K | $221.0K | $201.0K | $201.0K | |
| Total Assets | $117M | $191M | $252M | $270M | $332M | $366M | $103M | |
| Accounts Payable | $3M | $7M | $3M | $3M | $3M | $2M | $3M | |
| Accrued Liabilities | $8M | $7M | $10M | $7M | $9M | $5M | $2M | |
| Current Liabilities | $11M | $14M | $14M | $11M | $12M | $6M | $5M | |
| Capital Leases | $435.0K | $838.0K | $12M | $13M | $11M | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | $51.0K | |
| Total Liabilities | $12M | $15M | $26M | $24M | $23M | $6M | $5M | |
| Retained Earnings | $-446M | $-369M | $-310M | $-241M | $-168M | $-110M | $-75M | |
| AOCI | $84.0K | $139.0K | $224.0K | $-445.0K | $-78.0K | · | $-3.0K | |
| Stockholders' Equity | $105M | $176M | $226M | $246M | $309M | $359M | $-70M | |
| Liabilities + Equity | $117M | $191M | $252M | $270M | $332M | $366M | $103M | |
| Shares Outstanding | 53,331,766 | 51,935,134 | 51,445,862 | 45,771,332 | 45,433,684 | 44,777,818 | 3,046,200 |
现金流 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $6M | $9M | $12M | $10M | $5M | $2M | $908.0K | |
| Operating Cash Flow | $-74M | $-51M | $-56M | $-64M | $-47M | $-33M | $-22M | |
| CapEx | $29.0K | $655.0K | $962.0K | $8M | $1M | $148.0K | $109.0K | |
| Investing Cash Flow | $70M | $53M | $-51M | $-1M | $-144M | $28M | $3M | |
| Stock Issued | · | · | $35M | · | · | $223M | · | |
| Net Stock Activity | · | · | $35M | · | · | $223M | · | |
| Financing Cash Flow | $505.0K | $313.0K | $36M | $958.0K | $2M | $293M | $62M | |
| Net Change in Cash | $-3M | $2M | $-71M | $-64M | $-188M | $288M | $43M | |
| Taxes Paid | · | · | · | · | $23.0K | $6.0K | $8.0K | |
| Free Cash Flow | $-74M | $-52M | $-57M | $-72M | $-48M | $-33M | · |
盈利能力 7
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1360.4% | -802.0% | -717.3% | -2124.1% | -12982.8% | -5367.4% | · | |
| Net Margin | -1226.8% | -551.0% | -617.3% | -2021.4% | -12883.3% | -5290.3% | · | |
| Pretax Margin | -1261.1% | -702.1% | -617.3% | -2021.7% | -12878.2% | -5289.4% | · | |
| EBITDA Margin | -1360.4% | -802.0% | -717.3% | -2124.1% | -12982.8% | -5367.4% | · | |
| ROA | -50.5% | -26.5% | -26.4% | -24.4% | -16.6% | -14.7% | · | |
| ROE | -63.4% | -31.4% | -29.8% | -28.9% | -18.3% | -9.5% | · | |
| ROIC | -80.1% | -38.1% | -35.5% | -31.3% | -18.9% | -9.7% | · |
流动性与偿付能力 2
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.1 | 12.2 | 14.8 | 22.8 | 24.7 | 56.9 | · | |
| Quick Ratio | 9.9 | 11.8 | 14.5 | 22.3 | 24.3 | 56.4 | · |
效率 1
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | · |
增长率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -40.5% | -4.6% | 208.0% | 707.8% | -31.0% | · | · | |
| Revenue CAGR 3Y | 20.4% | 187.4% | 157.9% | · | · | · | · | |
| Revenue CAGR 5Y | 57.6% | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $11M | $11M | $4M | $449.0K | $651.0K | · | |
| Net Income TTM | $-78M | $-59M | $-69M | $-73M | $-58M | $-34M | · | |
| Market Cap | $67M | $78M | $159M | $398M | $1.05B | $2.75B | · | |
| P/E | -0.8 | -1.3 | -2.2 | -5.4 | -18.0 | -25.6 | · | |
| P/S | 10.5 | 7.4 | 14.3 | 109.8 | 2337.5 | 4230.9 | · | |
| P/B | 0.6 | 0.4 | 0.7 | 1.6 | 3.4 | 7.7 | · | |
| P / Tangible Book | 0.6 | 0.4 | 0.7 | 1.6 | 3.4 | 7.7 | · | |
| P / Cash Flow | -0.9 | -1.5 | -2.9 | -6.2 | -22.5 | -84.1 | · | |
| P / FCF | -0.9 | -1.5 | -2.8 | -5.6 | -21.9 | -83.7 | · | |
| Earnings Yield | -118.4% | -75.5% | -46.5% | -18.5% | -5.5% | -3.9% | · |
损益表 13
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $15M | $15M | $16M | $18M | $18M | $17M | $14M | $17M | $15M | $13M | $13M | $14M | $14M | $15M | $15M | $14M | |
| SG&A Expense | $4M | $4M | $3M | $4M | $4M | $4M | $11M | $5M | $6M | $5M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Operating Expenses | $19M | $19M | $19M | $23M | $23M | $22M | $25M | $22M | $20M | $18M | $19M | $20M | $20M | $21M | $21M | $19M | |
| Operating Income | $-19M | $-19M | $-19M | $-23M | $-23M | $-22M | $-25M | $-22M | $-20M | $-18M | $-19M | $-20M | $-20M | $-21M | $-21M | $-19M | |
| Other Non-op | $798.0K | $981.0K | $1M | $1M | $2M | $2M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Pretax Income | $-18M | $-18M | $-18M | $-21M | $-21M | $-20M | $-23M | $-19M | $-17M | $-15M | $-16M | $-17M | $-17M | $-19M | $-19M | $-18M | |
| Income Tax | $3.0K | · | $26.0K | $-6.0K | $5.0K | $-2M | $0 | $74.0K | $-16M | · | $-1.0K | $-1.0K | $4.0K | · | $0 | $-9.0K | |
| Net Income | $-18M | $-18M | $-18M | $-21M | $-21M | $-17M | $-23M | $-19M | $-1M | $-15M | $-16M | $-17M | $-17M | $-19M | $-19M | $-18M | |
| EPS (Basic) | $-0.34 | $-0.34 | $-0.33 | $-0.40 | $-0.41 | $-0.34 | $-0.45 | $-0.37 | $-0.02 | $-0.30 | $-0.30 | $-0.34 | $-0.38 | $-0.42 | $-0.42 | $-0.40 | |
| EPS (Diluted) | $-0.34 | $-0.34 | $-0.33 | $-0.40 | $-0.41 | $-0.34 | $-0.45 | $-0.37 | $-0.02 | $-0.30 | $-0.30 | $-0.34 | $-0.38 | $-0.42 | $-0.42 | $-0.40 | |
| Shares (Basic) | 53,386,909 | 53,331,766 | -104,414,514 | 52,993,238 | 52,010,827 | 51,952,062 | -102,919,833 | 51,574,027 | 51,478,751 | 51,445,862 | -92,619,140 | 49,047,296 | 45,813,132 | 45,773,357 | -91,065,244 | 45,622,957 | |
| Shares (Diluted) | 53,386,909 | 53,331,766 | -104,414,514 | 52,993,238 | 52,010,827 | 51,952,062 | -102,919,833 | 51,574,027 | 51,478,751 | 51,445,862 | -92,619,140 | 49,047,296 | 45,813,132 | 45,773,357 | -91,065,244 | 45,622,957 | |
| EBITDA | $-19M | $-19M | · | $-23M | $-23M | $-22M | · | $-22M | $-20M | $-18M | · | $-20M | $-20M | $-21M | · | $-19M |
资产负债表 19
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $12M | $39M | $38M | $36M | $44M | $51M | $41M | $49M | $49M | $48M | · | $52M | $68M | $143M | · | $100M | |
| Short-term Investments | $67M | $54M | $75M | $93M | $98M | $109M | $129M | $134M | $164M | $150M | · | $150M | $119M | $86M | · | $159M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $3M | $3M | $6M | $6M | $5M | $4M | · | $3M | $3M | $3M | · | $5M | |
| Current Assets | $81M | $96M | $115M | $132M | $145M | $163M | $176M | $190M | $219M | $202M | · | $205M | $190M | $233M | · | $265M | |
| PP&E (Net) | $154.0K | $203.0K | $237.0K | $255.0K | $287.0K | $376.0K | $409.0K | $10M | $11M | $11M | · | $11M | $11M | $11M | · | $10M | |
| PP&E (Gross) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $14M | $15M | $15M | · | $14M | $14M | $14M | · | $12M | |
| Accum. Depreciation | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $4M | $4M | $4M | · | $3M | $3M | $2M | · | $2M | |
| Other Non-current Assets | $296.0K | $296.0K | $297.0K | $249.0K | $248.0K | $237.0K | $235.0K | $242.0K | $182.0K | $182.0K | · | $180.0K | $181.0K | $314.0K | · | $307.0K | |
| Total Assets | $82M | $97M | $117M | $134M | $153M | $171M | $191M | $223M | $238M | $237M | · | $261M | $242M | $254M | · | $285M | |
| Accounts Payable | $2M | $2M | $3M | $3M | $3M | $4M | $7M | $2M | $5M | $859.0K | · | $2M | $3M | $2M | · | $5M | |
| Accrued Liabilities | $8M | $7M | $8M | $9M | $9M | $6M | $7M | $10M | $6M | $10M | · | $9M | $8M | $9M | · | $6M | |
| Current Liabilities | $11M | $9M | $11M | $12M | $12M | $10M | $14M | $14M | $11M | $12M | · | $11M | $11M | $11M | · | $12M | |
| Capital Leases | $0 | $0 | $435.0K | $541.0K | $643.0K | $742.0K | $838.0K | $12M | $12M | $12M | · | $13M | $13M | $13M | · | $12M | |
| Total Liabilities | $11M | $9M | $12M | $13M | $12M | $11M | $15M | $26M | $23M | $24M | · | $23M | $24M | $24M | · | $24M | |
| Retained Earnings | $-483M | $-464M | $-446M | $-428M | $-407M | $-386M | $-369M | $-346M | $-326M | $-325M | · | $-294M | $-278M | $-260M | · | $-222M | |
| AOCI | $-82.0K | $-15.0K | $84.0K | $91.0K | $21.0K | $84.0K | $139.0K | $410.0K | $-185.0K | $-129.0K | · | $-355.0K | $-328.0K | $-116.0K | · | $-1M | |
| Stockholders' Equity | $72M | $88M | $105M | $121M | $141M | $160M | $176M | $198M | $214M | $213M | $226M | $238M | $218M | $230M | $246M | $261M | |
| Liabilities + Equity | $82M | $97M | $117M | $134M | $153M | $171M | $191M | $223M | $238M | $237M | · | $261M | $242M | $254M | · | $285M | |
| Shares Outstanding | 53,460,432 | 53,331,766 | 53,331,766 | 52,993,238 | 52,993,238 | 51,954,135 | 51,935,134 | 51,749,504 | 51,522,125 | 51,445,862 | · | 51,157,636 | 46,143,536 | 45,774,761 | · | 45,624,860 |
现金流 8
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $2M | $1M | $1M | $1M | $2M | $2M | $1M | $2M | $3M | $3M | $3M | $3M | $3M | $3M | $3M | $2M | |
| Operating Cash Flow | $-15M | $-20M | $-17M | $-20M | $-18M | $-18M | $-17M | $-17M | $-2M | $-16M | $-12M | $-16M | $-13M | $-15M | $-15M | $-17M | |
| CapEx | $0 | $0 | $15.0K | $-1.0K | $11.0K | $4.0K | $56.0K | $1.0K | $4.0K | $594.0K | $197.0K | $44.0K | $565.0K | $156.0K | $2M | $2M | |
| Investing Cash Flow | $-12M | $21M | $18M | $12M | $11M | $29M | $8M | $17M | $2M | $26M | $-3M | $-34M | $-64M | $50M | $23M | $30M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | $0 | $33M | · | · | · | · | |
| Financing Cash Flow | $143.0K | $0 | $392.0K | $0 | $103.0K | $10.0K | $172.0K | $0 | $141.0K | $0 | $288.0K | $33M | $2M | $12.0K | $548.0K | $6.0K | |
| Net Change in Cash | $-27M | $1M | $2M | $-8M | $-7M | $10M | $-9M | $284.0K | $872.0K | $10M | $-14M | $-16M | $-75M | $35M | $8M | $13M | |
| Free Cash Flow | · | $-20M | · | · | · | $-18M | · | · | · | $-17M | · | · | · | $-15M | · | · |
盈利能力 7
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2396.1% | -1940.7% | · | -1521.8% | -1353.8% | -1114.4% | · | -837.0% | -720.1% | -617.2% | · | -657.8% | -746.4% | -923.9% | · | -1723.8% | |
| Net Margin | -2295.2% | -1840.6% | · | -1422.9% | -1255.0% | -901.1% | · | -735.2% | -43.3% | -517.3% | · | -557.6% | -646.7% | -822.7% | · | -1621.8% | |
| Pretax Margin | -2294.8% | -1840.6% | · | -1423.3% | -1254.7% | -1014.6% | · | -732.4% | -620.7% | -517.3% | · | -557.6% | -646.6% | -822.7% | · | -1622.6% | |
| EBITDA Margin | -2396.1% | -1940.7% | · | -1521.8% | -1353.8% | -1114.4% | · | -837.0% | -720.1% | -617.2% | · | -657.8% | -746.4% | -923.9% | · | -1723.8% | |
| ROA | -15.4% | -13.5% | · | -11.8% | -10.9% | -8.6% | · | -7.9% | -0.51% | -5.5% | · | -6.5% | -6.4% | · | · | -5.8% | |
| ROE | -17.1% | -14.5% | · | -13.2% | -11.9% | -9.3% | · | -8.8% | -0.56% | -6.0% | · | -7.1% | -7.0% | · | · | -6.2% | |
| ROIC | -26.4% | · | · | -18.6% | -16.3% | -12.0% | · | -11.1% | -0.66% | · | · | · | -9.2% | · | · | -7.4% |
流动性与偿付能力 2
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 7.7 | 11.1 | · | 10.8 | 12.5 | 16.8 | · | 14.0 | 19.2 | 16.8 | · | 19.2 | 16.6 | · | · | 22.8 | |
| Quick Ratio | 7.5 | 10.9 | · | 10.5 | 12.3 | 16.4 | · | 13.5 | 18.7 | 16.4 | · | 18.8 | 16.3 | · | · | 22.2 |
效率 1
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | 0.0 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $5M | $6M | · | $8M | $9M | $10M | · | $11M | $11M | $11M | · | $9M | $7M | $4M | · | $2M | |
| Net Income TTM | $-78M | $-78M | · | $-79M | $-59M | $-53M | · | $-52M | $-51M | $-68M | · | $-71M | $-72M | $-73M | · | $-69M | |
| Market Cap | $72M | $66M | · | $74M | $56M | $57M | · | $77M | $83M | $87M | · | $314M | $289M | · | · | $543M | |
| P/E | -0.9 | -0.8 | · | -0.9 | -0.9 | -1.1 | · | -1.4 | -1.6 | -1.2 | · | -4.0 | -4.0 | -3.0 | · | -7.8 | |
| P/S | 14.5 | 10.9 | · | 9.6 | 6.2 | 5.5 | · | 6.8 | 7.3 | 8.0 | · | 34.4 | 42.8 | · | · | 263.7 | |
| P/B | 1.0 | 0.8 | · | 0.6 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 1.3 | 1.3 | · | · | 2.1 | |
| P / Tangible Book | 1.0 | 0.8 | · | 0.6 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 1.3 | 1.3 | · | · | 2.1 | |
| P / Cash Flow | · | -3.4 | · | · | · | -3.1 | · | · | · | -5.4 | · | · | · | · | · | · | |
| P / FCF | · | -3.4 | · | · | · | -3.1 | · | · | · | -5.2 | · | · | · | · | · | · | |
| Earnings Yield | -111.2% | -120.2% | · | -108.6% | -107.5% | -94.5% | · | -69.1% | -64.2% | -84.7% | · | -25.1% | -25.2% | -33.8% | · | -12.8% |
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 营业利润率 % | -1360.4% | -802.0% | -717.3% | -2124.1% | -12982.8% |
| 净收入 | $-78M | $-59M | $-69M | $-73M | $-58M |
| 稀释后每股收益 (EPS) | $-1.48 | $-1.14 | $-1.44 | $-1.61 | $-1.28 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 10.1 | 12.2 | 14.8 | 22.8 | 24.7 |
| 速动比率 | 9.9 | 11.8 | 14.5 | 22.3 | 24.3 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $-74M | $-52M | $-57M | $-72M | $-48M |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
📊
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存，并会跟随您浏览所有股票。
机构持有人 (13F) 69 家申报者 · $42.8M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 8 (-5 与上一季度对比) | 8 (0 与上一季度对比) | 12 (-8 与上一季度对比) | 21 (+8 与上一季度对比) | +605K |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
公司内部人士 15 位内幕人士 · 4 位高管 · 9 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Michael Carulli | Chief Financial Officer | 2024年1月18日 A | 91286 | 0 | 0 | $0 |
| Winston Kung | COO, CFO | 2023年5月12日 A | 10600 | 0 | 0 | $0 |
| Deepika Jalota | Chief Development Officer | 2024年1月18日 A | 125501 | 0 | 0 | $0 |
| Leila Alland | Chief Medical Officer | 2023年9月15日 S | 45909 | 0 | 0 | $0 |
| Kirsten Flowers | 董事 | 2026年6月4日 A | — | 0 | 0 | $0 |
| Laurie Stelzer | 董事 | 2026年6月4日 A | — | 0 | 0 | $0 |
| Charles M Baum | 董事 | 2026年6月4日 A | — | 0 | 0 | $0 |
| Carol Giltner Gallagher | 董事 | 2026年6月4日 G | — | 0 | 0 | $0 |
| Arnold J Levine | 董事 | 2026年6月4日 A | 409842 | 0 | 0 | $0 |
| Richard A. Heyman | 董事 | 2023年6月8日 A | 0 | 0 | 0 | $0 |
| Peter A. Thompson | 董事 | 2022年6月2日 A | 475000 | 0 | 0 | $0 |
| Thilo Schroeder | 董事 | 2021年10月6日 S | 1101283 | 0 | 0 | $0 |
| Arnold L Oronsky | 董事 | 2020年9月29日 C | 6469911 | 0 | 0 | $0 |
| David Henry Mack | — | 2026年3月5日 A | 451109 | 0 | 0 | $0 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | — | 2020年9月29日 C | 760267 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
激进投资者及 5%+ 股东 1 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC, ORBIMED CAPITAL GP V LLC ×5 申报 | 2026年3月4日 | 0.00% | 修订 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 3 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。